Regulatory efforts in Japan converging to bolster biopharma
By Catherine Makino
Thursday, June 5, 2014
TOKYO - Japan's drug approval process has come a long way, marking a shift in the mindset at Japan's Pharmaceuticals and Medical Device Agency (PMDA).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.